newsfilter
← Latest News
GlobeNewswire·

Amplia Enters into Second Agreement with Korean Specialist Drug Screening Company Next&Bio to Explore Combination Therapy with FAK Inhibitor and kRAS Inhibitors

HIGHLIGHTS The preclinical research collaboration with specialist drug screening company Next & Bio has been extendedThe collaboration explores the effect of Amplia's FAK inhibitors in combination with experimental